- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Avantor Inc(AVTR)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for AVTR
11/18/2026: AVTR (3-star) is a SELL. SELL for 4 days. Simulated Profits (70.39%). Updated daily EoD!
Avantor Inc is a global life sciences tools and distribution company that provides mission-critical products, consumables, and services to biopharma and advanced technology markets. The company's primary strengths lie in its entrenched VWR global distribution network and essential single-use biomanufacturing solutions, which support steady cash generation. Its main investment story centers on operational turnarounds like the Revival program and recovering biopharma research pipelines driving organic growth. However, key risks include elevated debt leverage, choppy historical growth, and intense competition from larger industry peers. The stock suits growth-oriented or conditional momentum investors monitoring execution milestones and debt reduction progress.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | Top-line growth has been cyclical and muted recently, though organic growth is showing signs of recovery. |
| Momentum investor | Strong fit while signal remains positive | Positive earnings surprises and upward guidance revisions can trigger short-term upward momentum. |
| Value investor | Mixed fit | While free cash flow is robust, debt levels require careful valuation scrutiny. |
| Dividend investor | Weak fit | The company does not currently pay a dividend, focusing free cash flow on deleveraging. |
| Low-risk investor | Weak fit | Exposure to biopharma research cycles and debt leverage introduce notable equity volatility. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | Medium / high | The stock reacts sensitively to biopharma funding cycles and quarterly margin adjustments. |
| Valuation risk | Medium | Valuation relies heavily on successful execution of margin expansion and debt reduction targets. |
| Competition risk (large life sciences conglomerates) | High | Competing against larger, deeply entrenched players can pressure pricing power and market share. |
| Business quality | Medium / high | The sticky nature of laboratory distribution provides a solid operational foundation. |
| Dividend income | Low / none | No dividend is paid to common shareholders due to debt covenants and capital allocation strategy. |
| Execution risk | Medium / high | Successful turnaround implementation is critical to restoring historical profitability peaks. |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 10.29B USD | Price to earnings Ratio 30.36 | 1Y Target Price 17.35 |
Price to earnings Ratio 30.36 | 1Y Target Price 17.35 | ||
Volume (30-day avg) 9.3M shares | Beta 0.95 | 52 Weeks Range 7.26 - 17.45 | Updated Date 11/18/2026 |
52 Weeks Range 7.26 - 17.45 | Updated Date 11/18/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.5 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 62.0%
- Active BUY / eligible
- 67 / 108
- 30-Day BUY Count Change
- +22
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Medical Instruments & Supplies
- BUY participation
- 50.0%
- Active BUY / eligible
- 3 / 6
- 30-Day BUY Count Change
- +1
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.

Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type Stock | Historic Profit 7.66% | Avg. Invested days 40 | Today’s Advisory SELL |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| VWR Distribution & Services | Procurement, laboratory supplies, chemicals, safety gear, and custom onsite management services. | This is the core wholesale engine providing steady recurring volume across global research labs. |
| Bioscience & Medtech Products | Proprietary single-use assemblies, high-purity reagents, and filtration media for drug manufacturing. | Higher-margin proprietary products tied directly to commercial biopharmaceutical production. |
| Geographic Exposure (Americas & International) | Operations spanning North America, Europe, and AMEA, serving over 180 countries. | Balanced global footprint exposed to international healthcare spending and research hubs. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2026-10-28 | When Before Market | Estimate 0.21 | Actual 0.22 |
Profitability
Profit Margin 5.08% | Operating Margin (TTM) 7.96% |
Management Effectiveness
Return on Assets (TTM) 2.83% | Return on Equity (TTM) 5.91% |
Valuation
Trailing PE 30.36 | Forward PE 17.42 | Enterprise Value 13.60B | Price to Sales(TTM) 1.55 |
Enterprise Value 13.60B | Price to Sales(TTM) 1.55 | ||
Enterprise Value to Revenue 2.05 | Enterprise Value to EBITDA 15.16 | Shares Outstanding 677.62M | Shares Floating 658.76M |
Shares Outstanding 677.62M | Shares Floating 658.76M | ||
Percent Insiders 1.53 | Percent Institutions 101.81 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

